BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31179242)

  • 1. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.
    Kim SH; Park WS; Park B; Pak S; Chung J
    Front Oncol; 2019; 9():413. PubMed ID: 31179242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
    Kim SH; Kim JK; Park EY; Joo J; Lee KH; Seo HK; Joung JY; Chung J
    PLoS One; 2019; 14(2):e0211105. PubMed ID: 30785902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
    You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
    Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
    World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 10. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
    Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
    Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
    Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
    Mol Clin Oncol; 2017 Sep; 7(3):454-460. PubMed ID: 28781819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).
    Stellato M; Santini D; Verzoni E; De Giorgi U; Pantano F; Casadei C; Fornarini G; Maruzzo M; Sbrana A; Di Lorenzo G; Soraru M; Naglieri E; Buti S; De Vivo R; Napolitano A; Vignani F; Mucciarini C; Grillone F; Roviello G; Di Napoli M; Procopio G
    Front Oncol; 2021; 11():682449. PubMed ID: 34168997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.
    Kim SH; Suh YS; Lee DE; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    Oncotarget; 2017 Nov; 8(55):93633-93643. PubMed ID: 29212178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.
    Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L
    Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.